Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and thank you for standing by. My name is Bella, and I will be your conference operator today. At this time, I would like to welcome everyone to SOAP Therapeutics' first quarter 2026 business and financial update conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. We do request for today's session that you please limit to two questions only. If you would like to ask a question during this time, simply press star, then the number one or telephone keypad. To withdraw your question, press star one again. I would now like to turn the conference over to Thomas Leggett. Chief Financial Officer, you may begin. Good afternoon and welcome to Stoke Therapeutics' first quarter 2026 Business Update conference call. I'm Thomas Leggett, Chief Financial Officer of Stoke Therapeutics. Joining me on today's call are Ian Smith, our Chief Executive Officer, Dr. Barry Tico, Chief Medical Officer, and Jason Hoyt, Chief Patient Officer. As a reminder, today's webcast presentation is available in the Investors section of our website. This webcast is being recorded and will be available for replay later this evening. Before we begin, please note that today's discussion includes forward-looking statements. These forward-looking statements are subject to risks and uncertainties, and actual results may differ materially. Please refer to our filings of the SEC for additional information. With that, I'll turn the call over to Ian. Welcome, everyone, and thank you for joining us this evening. On today's call, we will review recent progress with our business. In a few minutes, Barry will review new top-line four-year longitudinal data from our ongoing Phase 1-2 Open Label Extension Stu...